First Batch of Merck Oral COVID-19 Drugs Arrives 新冠口服藥默沙東今抵台 首批1萬份

The first batch of Merck's oral COVID-19 medication arrived at Taoyuan International Airport on Jan. 24. The CECC purchased 10,000 doses. The mediation is suitable for treating mild to moderate cases within five days of onset.


The first batch of Merck's oral COVID-19 medication procured by Taiwan arrived at Taoyuan International Airport at 5:18 a.m. on Jan. 24 from Chicago aboard an EVA Air cargo plane. The flight was scheduled to arrive on Jan. 23, but was delayed due to aviation safety concerns over the U.S.' 5G rollout. The Central Epidemic Command Center purchased a total of 10,000 doses. Clinical trials showed the medication is suitable for treating adults with mild to moderate cases at risk of severe illness within five days of onset and who are not clinically suitable for other treatment methods.

Lee Ping-ing, Member, Specialist Advisory Panel, CECC: “The suitable targets are mild cases within five days of onset, because antiviral drugs should be immediately used to inhibit viral replication during the first few days after infection to see a healing effect. If the case has already progressed into an acute case and the five days have passed, then the efficacy won't be as noticeable.”

Huang Li-min, Honorary Chair, Infectious Diseases Society of Taiwan: “It can be used at quarantine hotels or centralized quarantine facilities. If doctors determine people have risk factors and they meet the criteria set by the central government, then these people can isolate while taking the medicine.”

The domestic epidemic situation is worsening rapidly. CECC member Lee Ping-ing said Taiwan is currently going through a transition period where communities and the virus co-exist. The basic condition for co-existence is that the number of acute cases and mortality rate do not exceed those of the flu. The flu's mortality rate is less than one per thousand. The key lies with the 20 percent of people who are unvaccinated. There are many active transmission chains with unknown origins. Doctors say epidemic investigations are using up a lot of medical resources.

Chiang Kuan-yu, Doctor, Taipei City Hospital: “These epidemic investigations are consuming a huge amount of epidemic investigation personnel. We can see how much they can accomplish, but we're very worried about when it will become unsustainable.”

Many people will be returning home for the Lunar New Year and gathering with family. Doctors urge people to avoid going to public places and gatherings.

 

 

 

 

清晨5時18分,國內首批默沙東口服抗病毒藥物,搭乘長榮航空BR-641貨機,從美國芝加哥運抵桃園機場,原本班機預計在昨天23日抵達,但受到美國5G影響飛安疑慮,延誤到今天抵台,指揮中心共採購一萬份,主要適用於發病5天內、具有重症風險因子,而且臨床上不適用其他治療方式的輕度到中度確診的成人。

指揮中心專家諮詢小組委員李秉穎表示:「適用對象主要還是在輕症發病前5天,因為就是要在受到感染的前面幾天,馬上用抗病毒的藥物,去壓制病毒的繁殖才會看到療效。如果你已經進展成重症,已經過了5天以上的話,可能就比較不會看出效果。」

台灣感染症醫學會名譽理事長黃立民:「在防疫旅館或在檢疫所都可以使用,如果醫師看過覺得他有危險因子,那也符合中央所訂的使用的原則,那他就可以一面隔離、一面吃藥就可以了。」

本土疫情多點爆發,李秉穎表示台灣正在歷經社區與病毒共存的過渡期,國內疫情與病毒共存的基本條件,就是重症與死亡率不超過流感,而以流感來說死亡率是小於千分之一,關鍵仍在於那2成尚未接種疫苗的國人,對於多條傳播鏈感染源不明,有醫師認為積極疫調也同時耗費大量醫療量能。

台北市聯合醫院主治醫師姜冠宇指出:「這些疫調的過程中,其實也是我們疫調人力的一個很大的耗費,所以看能做到多少,當我們疫調人力沒辦法負荷的時候,就要很當心。」

農曆過年碰上返鄉人潮,和親人見面是人之常情,不過醫師也呼籲,民眾在近期仍要盡量減少出入公共場合,以避免群聚增加染疫風險也消耗醫療人力。

 

相關新聞